Detalles de la búsqueda
1.
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet
; 401(10394): 2138-2147, 2023 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37321235
2.
A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients.
Crit Care
; 21(1): 22, 2017 02 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28159015
3.
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults.
J Travel Med
; 31(2)2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38091981
4.
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies.
Lancet Infect Dis
; 2024 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38830375
5.
Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults.
Lancet Infect Dis
; 23(10): 1186-1196, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37419129
6.
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
J Infect
; 87(3): 242-254, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37406777
7.
Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera.
JCI Insight
; 7(14)2022 07 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35700051
8.
A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine.
J Travel Med
; 2022 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36377643
9.
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lancet Infect Dis
; 22(12): 1716-1727, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36075233
10.
Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
J Infect
; 85(3): 306-317, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35718205
11.
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial.
Lancet Infect Dis
; 20(10): 1193-1203, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32497524
12.
Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers.
Vaccine
; 34(23): 2585-92, 2016 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27079932
13.
Design of protective and therapeutic DNA vaccines for the treatment of allergic diseases.
Curr Drug Targets Inflamm Allergy
; 4(5): 585-97, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16248827
14.
A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
Hum Vaccin Immunother
; 10(1): 170-83, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24064511
15.
Murine gammaherpesvirus-68 productively infects immature dendritic cells and blocks maturation.
J Gen Virol
; 88(Pt 7): 1896-1905, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17554020
16.
TH1-promoting DNA immunization against allergens modulates the ratio of IgG1/IgG2a but does not affect the anaphylactic potential of IgG1 antibodies: no evidence for the synthesis of nonanaphylactic IgG1.
J Allergy Clin Immunol
; 112(3): 579-84, 2003 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-13679818
17.
Quantification of histamine in blood plasma and cell culture supernatants: a validated one-step gas chromatography-mass spectrometry method.
Anal Biochem
; 308(2): 300-6, 2002 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12419343
18.
DNA vaccines for allergy treatment.
Methods
; 32(3): 328-39, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-14962768
19.
Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
Eur J Immunol
; 33(6): 1667-76, 2003 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-12778485
20.
Strategies for the development of safe and effective DNA vaccines for allergy treatment.
Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M
; (94): 279-98; discussion 299, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-15119049